Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 4, 2026Reported sale · Form 4Lloyd Minor · $119.2KOpen the filing ↗
- Aug 4, 2026Notice of sale · Form 144Minor Lloyd · Director · $119.2KOpen the filing ↗
- Aug 3, 2026Reported sale · Form 4Lloyd Minor · $120.6KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record2,4289 flagged findings
Reported transactions (Form 4)80since Feb 6, 2026 · and 18 other holdings
Corporate events (8-K)30since Oct 1, 2019
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
The 25 most recent filings (of 2,428)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Aug 12, 26Form 3 ↗Insider transaction
- Aug 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 12.4% · event on Jun 30, 26 · amendment
- Aug 5, 26Form 4 ↗Insider transaction
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Aug 4, 26Form 144 ↗Notice of proposed sale
- Aug 3, 26Form 144 ↗Notice of proposed sale
- Jul 29, 2610-Q ↗Quarterly report
- Jul 29, 268-K ↗Current report · Results
- Jul 1, 268-K ↗Current report · Results
Insider transaction · 9 Form 4 filingsshow all 9hide
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 4 ↗Insider transaction
- Jun 10, 268-K ↗Current report · Shareholder vote results
- Jun 10, 268-K/A ↗Current report · Financial statements and exhibits · amendment
- Jun 5, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 11.3% · event on May 29, 26 · amendment
- May 14, 268-K ↗Current report · Took on a new financial obligation
- May 14, 26SC TO-T/A ↗Merger, acquisition or tender offer · amendment
- May 14, 26SCHEDULE 13D/A ↗Stake with intent to influence · amendment
2,428 filings on record, the oldest from May 21, 96.
Listing the 25 most recent filings of the 2,428 on record.
44660
- May 14, 26Took on a new financial obligation+4 more in the same filing8-K 2.03 ↗
- Mar 31, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
5 senior executive changes2024 – 2026show all 5hide
- Mar 11, 26A senior executive left or was appointed8-K 5.02 ↗
- Feb 11, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 15, 25A senior executive left or was appointed8-K 5.02 ↗
- Oct 30, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 12, 24A senior executive left or was appointed8-K 5.02 ↗
- Aug 14, 24Took on a new financial obligation+3 more in the same filing8-K 2.03 ↗
- Nov 8, 23A senior executive left or was appointed8-K 5.02 ↗
- Sep 1, 23Took on a new financial obligation+2 more in the same filing8-K 2.03 ↗
- Jul 31, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
10 senior executive changes2020 – 2023show all 10hide
- Mar 9, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Nov 10, 22A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 21, 22A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 3, 22A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 31, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Nov 17, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 9, 21A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 21, 20A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jul 22, 20A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 20, 20A senior executive left or was appointed8-K 5.02 ↗
- Feb 3, 20Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Oct 1, 19A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
The record reaches back to Sep 29, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Oct 21, 15Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Nov 3, 10Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Sep 13, 05Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Jun 16, 05Restructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
The full record holds 4 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- FMR LLC12.4%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
- PRIMECAP MANAGEMENT CO/CA/10.2%Sep 30, 25SCHEDULE 13G/A ↗
- BlackRock, Inc.8.5%Mar 31, 25SCHEDULE 13G/A ↗
- Vanguard Capital Management7.5%Mar 31, 26SCHEDULE 13G ↗
- STATE STREET CORPORATION5.0%Sep 30, 25SCHEDULE 13G ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 4, Minor Lloyd filed notice of intent to sell up to $119K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $119K on Aug 4, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+1 more recent notices · 1 with a later sale
Stock compensation, tax and giftsshow the 36 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 2, 26Compensationamount n/aSean GodboutChief Accounting Officer↗
- Oct 2, 26Tax$2KSean GodboutChief Accounting Officer↗
- Jun 9, 26Compensationamount n/aMaria C Freire↗
- Jun 9, 26Compensationamount n/aLloyd Minor↗
- Jun 9, 26Compensationamount n/aMenelas N Pangalos↗
- Jun 9, 26Compensationamount n/aMenelas N Pangalos↗
- Jun 9, 26Compensationamount n/aMonish D Patolawala↗
- Jun 9, 26Compensationamount n/aSUSAN LANGER↗
- Jun 9, 26Compensationamount n/aJesus B Mantas↗
- Jun 9, 26Compensationamount n/aEric K Rowinsky↗
- Jun 9, 26Compensationamount n/aSTEPHEN A SHERWIN↗
- Jun 9, 26Compensationamount n/aWILLIAM A HAWKINS↗
- May 1, 26Compensationamount n/aAdam KeeneyHead of Corporate Development↗
- May 1, 26Tax$85KAdam KeeneyHead of Corporate Development↗
- Apr 1, 26Compensationamount n/aSean GodboutChief Accounting Officer↗
- Apr 1, 26Tax$10KSean GodboutChief Accounting Officer↗
- Feb 6, 26Compensationamount n/aSUSAN H ALEXANDEREVP Chief Legal Officer↗
- Feb 6, 26Tax$213KSUSAN H ALEXANDEREVP Chief Legal Officer↗
- Feb 6, 26Compensationamount n/aSUSAN H ALEXANDEREVP Chief Legal Officer↗
- Feb 6, 26Tax$187KSUSAN H ALEXANDEREVP Chief Legal Officer↗
- Feb 6, 26Compensationamount n/aSUSAN H ALEXANDEREVP Chief Legal Officer↗
- Feb 6, 26Tax$305KSUSAN H ALEXANDEREVP Chief Legal Officer↗
- Feb 6, 26Compensationamount n/aSean GodboutChief Accounting Officer↗
- Feb 6, 26Tax$15KSean GodboutChief Accounting Officer↗
- Feb 6, 26Compensationamount n/aSean GodboutChief Accounting Officer↗
- Feb 6, 26Tax$21KSean GodboutChief Accounting Officer↗
- Feb 6, 26Compensationamount n/aSean GodboutChief Accounting Officer↗
- Feb 6, 26Tax$36KSean GodboutChief Accounting Officer↗
- Feb 6, 26Compensationamount n/aGinger GregoryEVP, Human Resources↗
- Feb 6, 26Tax$159KGinger GregoryEVP, Human Resources↗
- Feb 6, 26Compensationamount n/aGinger GregoryEVP, Human Resources↗
- Feb 6, 26Tax$134KGinger GregoryEVP, Human Resources↗
- Feb 6, 26Compensationamount n/aGinger GregoryEVP, Human Resources↗
- Feb 6, 26Tax$228KGinger GregoryEVP, Human Resources↗
- Feb 6, 26Compensationamount n/aJane GroganHead of Research↗
- Feb 6, 26Tax$82KJane GroganHead of Research↗
The full record holds 318 transactions and goes back to Jun 7, 22.
Its sector and its market
Biogen Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Biogen Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Biogen Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 2,428 documents on file, from May 21, 1996 to Oct 5, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.